Industry
Biotechnology
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Loading...
Open
55.09
Mkt cap
5.4B
Volume
1.4M
High
55.09
P/E Ratio
42.48
52-wk high
61.66
Low
51.51
Div yield
N/A
52-wk low
20.84
Portfolio Pulse from
November 11, 2024 | 2:00 pm
Portfolio Pulse from
November 08, 2024 | 1:30 pm
Portfolio Pulse from
November 06, 2024 | 1:00 pm
Portfolio Pulse from
November 05, 2024 | 7:00 pm
Portfolio Pulse from
November 05, 2024 | 6:15 pm
Portfolio Pulse from
November 05, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 8:43 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.